摘要
目的:探讨多肿瘤标志物C12蛋白芯片检测系统在胃肠癌的诊断价值。方法:分析总结329例胃肠癌初治患者C12芯片的检测结果,寻找出与胃肠癌相关性最强的肿瘤标志物,计算各种肿瘤标志物组合方式对提高诊断率的贡献。结果:C12系统对本组329例胃肠癌患者的总体诊断率为39.21%,Ⅰ、Ⅱ、Ⅲ、Ⅳ期患者的诊断率分别为13.73%、33.33%、38.30%、58.03%。肿瘤标志物阳性率在各临床分期中的整体差异具有统计学显著性(P<0.01),Ⅰ期与Ⅲ期、Ⅰ期与Ⅳ期、Ⅱ期与Ⅳ期差异具有统计学显著性(P<0.01),其余分期相比没有统计学显著性(P>0.05)。C12系统中阳性率最高的三种TM是CEA、CA242和CA19-9,阳性率分别为27.36%、19.76%和19.45%,并且与肿瘤的分期相关。结论:C12检测系统对晚期胃肠癌的诊断有一定的价值,但对早期的敏感性不高,临床迫切需要微型高效的胃肠癌检测系统。
Objective：To assess the value of tumor markers（TMs） protein chip diagnostic system C12 in the diagnosis of gastrointestinal cancer（GIC）. Methods ：The sera of 329 pathologically-confirmed GIC patients were detected by the C 12 protein biochip system. The most relevant TMs and the contribution of various combinations of TMs to the improvement of diagnosis were determined. Results：The diagnostic rates of C12 biochip system in 329 GIC patients were 13.73%,33.33%,38.30%,58.03% for stages Ⅰ , Ⅱ, Ⅲ and Ⅳ patients, respectively,and the overall diagnostic rate was 39.21%. There were statistically significant difference （P 〈 0.01） among all clinical stages （contingency table chi-square test）, stage Ⅰ versus stage Ⅲ ,stage Ⅰ versus stage IV ,and stage Ⅱ versus stage IV. The other comparisons didn＇t have statistical significance （P 〉 0.05）. Among all the 12 TMs,the top three positive rates of 27.36%, 19.76% and 19.45% were obtained from CEA, CA242 and CA 19-9, respectively,which were correlated with the stage of GIC. Conclusion：The C 12 biochip diagnostic system has some value in the diagnosis of advanced GIC, but its sensitivity for early stage is poor. The miniature and effective diagnostic system is needed in clinic urgently.
出处
《南京医科大学学报（自然科学版）》
CAS
CSCD
北大核心
2008年第10期1285-1289,共5页
Journal of Nanjing Medical University(Natural Sciences)
基金
荆门市科技计划项目(08S12)
教育部新世纪优秀人才支持计划(NCET-04-0669)
全国优秀博士学位论文作者专项资金资助项目(200464)
武汉市创新研究课题资助(20066002054)
关键词
胃癌
结直肠癌
肿瘤标志物
临床分期
蛋白芯片
gastric cancer
colorectal cancer
tumor marker
clinical staging
protein biochip
